CL2022002645A1 - Glucagon derivatives with improved stability - Google Patents

Glucagon derivatives with improved stability

Info

Publication number
CL2022002645A1
CL2022002645A1 CL2022002645A CL2022002645A CL2022002645A1 CL 2022002645 A1 CL2022002645 A1 CL 2022002645A1 CL 2022002645 A CL2022002645 A CL 2022002645A CL 2022002645 A CL2022002645 A CL 2022002645A CL 2022002645 A1 CL2022002645 A1 CL 2022002645A1
Authority
CL
Chile
Prior art keywords
glucagon
present
improved stability
hypoglycemia
prevention
Prior art date
Application number
CL2022002645A
Other languages
Spanish (es)
Inventor
Yun Kim Sang
Kuk Kim Jung
Min Lee Jong
Youb Jung Sung
Chang Kwon Se
Min Bae Sung
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Priority to CL2022002645A priority Critical patent/CL2022002645A1/en
Publication of CL2022002645A1 publication Critical patent/CL2022002645A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un nuevo péptido derivado del glucagón y a una composición para la prevención o el tratamiento de hipoglucemia, que contiene el nuevo péptido derivado del glucagón como principio activo. El derivado de glucagón de acuerdo con la presente invención tiene propiedades físicas mejoradas debido al cambio en el punto isoeléctrico (pI) mientras que es capaz de mantener una actividad en los receptores del glucagón y, por tanto, puede mejorar la conformidad del paciente cuando se usa como un agente hipoglucémico y también es adecuado para la administración en combinación con otros agentes antiobesidad. Por consiguiente, el derivado de glucagón de acuerdo con la presente invención se puede usar de manera eficaz para la prevención y el tratamiento de la hipoglucemia y la obesidad.The present invention relates to a new glucagon-derived peptide and to a composition for the prevention or treatment of hypoglycemia, which contains the new glucagon-derived peptide as an active ingredient. The glucagon derivative according to the present invention has improved physical properties due to the change in isoelectric point (pI) while being able to maintain an activity at glucagon receptors and thus can improve patient compliance when used. It is used as a hypoglycemic agent and is also suitable for administration in combination with other anti-obesity agents. Therefore, the glucagon derivative according to the present invention can be effectively used for the prevention and treatment of hypoglycemia and obesity.

CL2022002645A 2022-09-28 2022-09-28 Glucagon derivatives with improved stability CL2022002645A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CL2022002645A CL2022002645A1 (en) 2022-09-28 2022-09-28 Glucagon derivatives with improved stability

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2022002645A CL2022002645A1 (en) 2022-09-28 2022-09-28 Glucagon derivatives with improved stability

Publications (1)

Publication Number Publication Date
CL2022002645A1 true CL2022002645A1 (en) 2023-05-26

Family

ID=86558113

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002645A CL2022002645A1 (en) 2022-09-28 2022-09-28 Glucagon derivatives with improved stability

Country Status (1)

Country Link
CL (1) CL2022002645A1 (en)

Similar Documents

Publication Publication Date Title
CL2017001718A1 (en) Glucagon derivatives with improved stability
CL2021003419A1 (en) Glucagon-like peptide-1 receptor agonists
AR112480A1 (en) COMPOSITIONS OF GLP-1 AND ITS USES
AR026986A1 (en) PHARMACEUTICAL IMPLANT WITH CONTENT OF IMMEDIATE RELEASE AND SUSTAINED RELEASE COMPONENTS AND METHODS OF ADMINISTRATION
BRPI0704238A (en) preventive of coccidiosis and clostridial disease and / or therapy for coccidiosis and clostridial disease
BR112021002069A2 (en) Composition for hair treatment, methods and uses.
BR112015023071A2 (en) insulin-incretin conjugates
BR112018067896A2 (en) apparatus for subretinal administration of therapeutic agent through a curved needle
NI200800169A (en) USE OF BENZO-FUSED HETEROCYCLIC SULFAMID DERIVATIVES FOR THE TREATMENT OF PAIN
BRPI0513168A (en) memantine as adjunctive treatment for atypical antipsychotics in patients with schizophrenia
ECSP20070185A (en) NEW GLP-1 ANALOGUES
MX2019009922A (en) Oil based formulations for sublingual and buccal delivery.
AR062775A1 (en) PHARMACEUTICAL COMPOSITION ABLE TO IMPROVE THE ACTIVITY OF LPG -1 IN A HUMAN BEING AND ITS USE TO PREPARE A MEDICINAL PRODUCT
BR112018074108A2 (en) drug delivery syringes and exact dose control mechanisms
BR112023018842A2 (en) SELECTIVE DRUG RELEASE OF CONJUGATES
UY38067A (en) MODIFIED RELAXIN B-CHAIN PEPTIDES AND THEIR THERAPEUTIC USE
CL2022002646A1 (en) Glucagon derivatives with improved stability
CL2022002645A1 (en) Glucagon derivatives with improved stability
CL2022002644A1 (en) Glucagon derivatives with improved stability
AR110193A1 (en) INSULIN ANALOGS OF FAST STABILITY IMPROVED ACTION
AR048370A1 (en) COMPOSITION TO IMPROVE COGNITIVE FUNCTIONS AND MEMORY
EA202000347A1 (en) ANTI-SARS-CoV-2 VIRAL AGENT ANTIPROVIR
CL2022000320A1 (en) Compounds suitable for the treatment and prophylaxis of muscle wasting and other conditions
EP4338751A3 (en) Medicament comprising combination of sepetaprost and rho-associated coiled-coil containing protein kinase inhibitor
CU20200030A7 (en) PEPTIDE FOR THE TREATMENT OF INFECTIONS CAUSED BY CORONAVIRUS